Further investigation into how the common organism Escherichia coli regulates gene expression has given scientists new ideas for designing antibiotics that might drastically reduce a bacterium's ability to resist drugs.
The findings, reported in the current issue of the journal Cell, suggest that bacteria rely on a key protein in order to properly regulate gene expression -- a process fundamental to cell survival.
This protein, called DksA, coordinates the expression of numerous genes in response to environmental signals.
Figuring out how to block DksA production in harmful bacteria may help scientists develop antibiotics that these bacteria are less likely to resist, said Irina Artsimovitch, a study co-author and an assistant professor of microbiology at Ohio State University.
The current study suggests that DksA is the glue that holds together two key components of bacterial gene expression -- a molecule called ppGpp and an enzyme called RNA polymerase. RNA polymerase carries out transcription, the first step in gene expression.
In recent work, Artsimovitch and her colleagues discovered that ppGpp regulates gene expression by controlling amino acid production in bacteria. A cell makes ppGpp when amino acid levels are low, and ppGpp tells a cell to go dormant until amino acid levels return to normal.
"But there was something missing from the ppGpp story," Artsimovitch says. "We knew that ppGpp had a dramatic effect on gene expression, but for some reason that effect was drastically decreased when we conducted experiments in the laboratory."
Work by other researchers had suggested a link between DksA and the ppGpp-initiated stress response in the cell, but scientists could not agree on what role, if any, DksA played in the effect of ppGpp on gene expression.
Working with a team of researchers led by Dmitry Vassylyev, a scientist with the RIKEN research institution in Japan, Artsimovitch and Ohio State microbiologist Vladimir Svetlov solved high-resolution crystal structures of DksA.
Solving this structure meant that the researchers could at last determine just how DksA helped ppGpp hold fast to its target, RNA polymerase.
DksA uses something scientists call the "back door of gene expression," a cavity on the RNA polymerase molecule called the secondary channel. DksA squeezes through this narrow tunnel toward the site where ppGpp binds to the enzyme. Once there, the protein helps ppGpp stay bound to RNA polymerase.
"The secondary channel seems to be the hotspot for many interactions," Artsimovitch says. "It leads straight to the active site, and presents a confined area where many proteins and antibiotics that control transcription may bind to carry out their business."
Knowing what roles ppGpp and DksA play in how bacteria respond to stress and other physiological stimuli may help scientists create new antibacterial drugs that target mechanisms specific and unique to harmful bacteria.
"Conventional antibiotics aimed at killing bacteria also put immense pressure on bacteria to survive and to ultimately develop resistance to these drugs," Artsimovitch says. "Forcing harmful bacteria into a stationary state by controlling ppGpp levels may be the way to circumvent the rise in antibiotic resistance.
"ppGpp and DksA are found in all bacteria, including harmful ones," she continues. "Using ppGpp-based compounds to shut down gene expression in harmful bacteria could help curb the spread of infections."
Grants from the National Institutes of Health and from RIKEN supported this research.
Artsimovitch, Vassylyev and Svetlov conducted the study with Anna Perederina, Marina Vassylyeva, Tahir Tahirov and Shigeyuki Yokoyama, all with RIKEN.
Source: Ohio State University
Strengthening Defenses: Integrating Infection Control With Antimicrobial Stewardship
October 11th 2024Use this handout to explain the basics of why infection prevention and control and antimicrobial stewardship are essential and how the 2 fields must have a unified approach to patient and staff safety
Blood Product Overtransfusion Is a Global Issue: Here Are 5 Reasons the Practice Must Change
October 9th 2024If a patient receives treatment or therapy that they do not need, it can cause unnecessary harm. This is true for medications, surgeries, and medical procedures, especially blood transfusions.